Undetected Severe Fetal Myelosuppression following Administration of High-Dose Cytarabine for Acute Myeloid Leukemia: Is More Frequent Surveillance Necessary?

<div>MCA PSV measurements for Case  1. Vertical lines indicate the time of chemotherapy administration. PSV cm/s, peak systolic velocity measurement; MoM, multiples of mean of PSV measurement for corresponding gestational age.</div>

Case Reports in Obstetrics and Gynecology

fig1

Figure 1

Figure 1: Undetected Severe Fetal Myelosuppression following Administration of High-Dose Cytarabine for Acute Myeloid Leukemia: Is More Frequent Surveillance Necessary? 

Figure 1 | Undetected Severe Fetal Myelosuppression following Administration of High-Dose Cytarabine for Acute Myeloid Leukemia: Is More Frequent Surveillance Necessary? 